The progress of intra-arterial chemotherapy for retinoblastoma_Chinese Journal of Ocular Fundus Diseases

Authors：

XiaJiejun ,  ZhangJing

Interventional & Vascular Anomalies Department, Guangzhou Women & Children Medical Center, Guangzhou medical university, Guangzhou 510623, China;

Corresponding author：

ZhangJing, Email: fejr@foxmail.com

Keywords：

Retinoblastoma/therapy; Chemotherapy, cancer, regional perfusion; Review

DOI：

10.3760/cma.j.issn.1005-1015.2016.03.028

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Intra-arterial chemotherapy (IAC) is an interventional treatment for retinoblastoma (RB) which infuses the chemotherapeutic agents through ophthalmic artery using microcatheters to control the tumor. Compared with systemic chemotherapy, IAC could significantly increase the globe salvage of advanced and recurrent RB without serious adverse event. Due to the absence of systemic absorption after IAC, no longer effectively kill tumor cell, which have potential danger to leads to inadequate elimination extraocular tumor cells. The most common systemic complications following IAC is myelosuppression; local ocular toxicities include eyelid edema, delacrimation, blepharoptosis, vitreous hemorrhage, retinal artery obstruction. During the last 10 years of clinical application, IAC become one of first-line treatment for intraocular RB. However, at present, there is still a lack of randomized controlled multicenter studies and long-term follow up of IAC.

Citation： XiaJiejun, ZhangJing. The progress of intra-arterial chemotherapy for retinoblastoma. Chinese Journal of Ocular Fundus Diseases, 2016, 32(3): 330-333. doi: 10.3760/cma.j.issn.1005-1015.2016.03.028 Copy

1.	Tamboli D, Topham A, Singh N, et al. Retinoblastoma:a SEER dataset evaluation for treatment patterns, survival, and second malignant neoplasms[J]. Am J Ophthalmol, 2015, 160(5):953-958. DOI:10.1016/j.ajo.2015.07.037.
2.	Wong FL, Boice JJ, Abramson DH, et al. Cancer incidence after retinoblastoma:radiation dose and sarcoma risk[J]. JAMA, 1997, 278(15):1262-1267.
3.	Chan HS, Gallie BL, Munier FL, et al. Chemotherapy for retinoblastoma[J]. Ophthalmol Clin North Am, 2005, 18(1):55-63. DOI:10.1016/j.ohc.2004.11.002.
4.	Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma:is chemotherapy a factor?[J]. Ophthalmology, 2007, 114(7):1378-1383. DOI:10.1016/j.ophtha.2007.03.074.
5.	Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma:four-year experience[J]. Arch Ophthalmol, 2011, 129(6):732-737. DOI:10.1001/archophthalmol.2011.5.
6.	Francis JH, Abramson DH. Recent advances in retinoblastoma treatment[M]. Bolin:Springer International Publishing, 2015:27-36.
7.	Abramson DH, Shields CL, Munier FL, et al. Treatment of retinoblastoma in 2015:agreement and disagreement[J]. JAMA Ophthalmol, 2015, 133(11):1341-1347. DOI:10.1001/jamaophthalmol.2015.3108.
8.	Yousef YA, Soliman SE, Astudillo PP, et al. Intra-arterial chemotherapy for retinoblastoma:a systematic review[J/OL]. JAMA Ophthalmol, 2016, 2016:E1[2016-03-17]. http://archopht.jamanetwork.com/article.aspx?doi=10.1001/jamaophthalmol.2016.0244. DOI:10.1001/jamaophthalmol.2016.0244.[published online ahead of print].
9.	Gaudana R, Jwala J, Boddu SH, et al. Recent perspectives in ocular drug delivery[J]. Pharm Res, 2009, 26(5):1197-1216. DOI:10.1007/s11095-008-9694-0.
10.	Shields CL, Shields JA. Intra-arterial chemotherapy for retinoblastoma:the beginning of a long journey[J]. Clin Experiment Ophthalmol, 2010, 38(6):638-643. DOI:10.1111/j.1442-9071.2010.02297.x.
11.	Schaiquevich P, Buitrago E, Taich P, et al. Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients[J]. Invest Ophthalmol Vis Sci, 2012, 53(7):4205-4212. DOI:10.1167/iovs.12-9501.
12.	Taich P, Ceciliano A, Buitrago EEA. Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma[J]. Ophthalmology, 2014, 121(4):889-897. DOI:10.1517/17425255.2014.951330.
13.	Inomata M, Kaneko A. Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay[J]. Jpn J Cancer Res, 1987, 78(8):858-868.
14.	Rashid OM, Sloot S, Zager JS. Regional therapy in metastatic melanoma:an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion[J]. Expert Opin Drug Metab Toxicol, 2014, 10(10):1355-1364. DOI:10.1517/17425255.2014.951330.
15.	Francis JH, Abramson DH, Gaillard MC, et al. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan[J]. Ophthalmology, 2015, 122(6):1173-1179. DOI:10.1016/j.ophtha.2015.01.017.
16.	Reese AB, Hyman GA, Merriam GJ, et al. Treatment of retinoblastoma by radiation and triethylenemelamine[J]. AMA Arch Ophthalmol, 1954, 53(4):505-513.
17.	Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma[J]. Int J Clin Oncol, 2004, 9(2):69-73.
18.	Abramson DH, Dunkel IJ, Brodie SE, et al. A phaseⅠ/Ⅱstudy of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results[J]. Ophthalmology, 2008, 115(8):1398-1404. DOI:10.1016/j.ophtha.2007.12.014.
19.	Zanaty M, Barros G, Chalouhi N, et al. Update on intra-arterial chemotherapy for retinoblastoma[J/OL]. Sci World J, 2014, 2014:869604[2014-10-22]. http://www.hindawi.com/journals/tswj/2014/869604/. DOI:10.1155/2014/869604.
20.	李冬梅, 高艳红, 甘慢慢, 等.超选眼动脉介入灌注美法仑治疗视网膜母细胞瘤患儿的护理[J].中华护理杂志, 2014, 49(11):1356-1358. DOI:10.3761/j.issn.0254-1769.2014.11.016.Li DM, GaoYH, Gan MM, et al. Perioperative nursing of retinoblastoma patients treated by superselective ophthalmic artery infusion of melphalan[J]. Chin J Nurs, 2014, 49(11):1356-1358. DOI:10.3761/j.issn.0254-1769.2014.11.016.
21.	张靖, 姜华, 申刚, 等.经导管眼动脉灌注化疗治疗晚期视网膜母细胞瘤30例[J].介入放射学杂志, 2014, 23(1):31-34. DOI:10.3969/j.issn.1008-794X.2014.01.009.Zhang J, Jiang H, Shen G, et al. Selective ophthalmic arterial injection therapy for advanced retinoblastoma:initial experience in 30 cases[J]. J Intervent Radiol, 2014, 23(1):31-34. DOI:10.3969/j.issn.1008-794X.2014.01.009.
22.	Lumbroso-Le RL, Aerts I, Levy-Gabriel C, et al. Conservative treatments of intraocular retinoblastoma[J]. Ophthalmology, 2008, 115(8):1405-1411. DOI:10.1016/j.ophtha.2007.11.009.
23.	Shields CL, Mashayekhi A, Au AK, et al. The international classification of retinoblastoma predicts chemoreduction success[J]. Ophthalmology, 2006, 113(12):2276-2280. DOI:10.1016/j.ophtha.2006.06.018.
24.	Shields CL, Ramasubramanian A, Thangappan A, et al. Chemoreduction for group E retinoblastoma:comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes[J]. Ophthalmology, 2009, 116(3):544-551. DOI:10.1016/j.ophtha.2008.10.014.
25.	Shields CL, Manjandavida FP, Lally SE, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes:outcomes based on the international classification of retinoblastoma[J]. Ophthalmology, 2014, 121(7):1453-1460. DOI:10.1016/j.ophtha.2014.01.026.
26.	Francis JH, Abramson DH, Gobin YP, et al. Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma[J]. Ophthalmology, 2015, 122(5):1016-1022. DOI:10.1016/j.ophtha.2014.11.029.
27.	季迅达, 李家恺, 赵军阳, 等.眼内晚期视网膜母细胞瘤静脉化学治疗失败后行眼动脉介入化学治疗的疗效观察[J].中华眼底病杂志, 2015, 31(6):556-559. DOI:10.3760/cma.j.issn.1005-1015.2015.06.011.Ji XD, Li JK, Zhao JY, et al.Efficacy of intra-arterial chemotherapy for advanced retinoblastoma after failure of intravenous chemotherapy[J]. Chin J Ocul Fundus Dis, 2015, 31(6):556-559. DOI:10.3760/cma.j.issn.1005-1015.2015.06.011.
28.	刘秋玲, 王亚峰, 毛更生, 等.眼动脉介入化疗治疗眼内期视网膜母细胞瘤42例临床安全性分析[J].中华儿科杂志, 2012, 50(10):793-797. DOI:10.3760/cma.j.issn.0578-1310.2012.10.019.Liu QL, Wang YF, Mao GS, et al.Analysis on the safety of ophthalmic artery cannulation for intra-arterial chemotherapy in 42 patients with intraocular stage retinoblastoma[J]. Chin J Pediatr, 2012, 50(10):793-797.DOI:10.3760/cma.j.issn.0578-1310.2012.10.019.
29.	Abramson DH, Marr BP, Dunkel IJ, et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding:2-year results[J]. Br J Ophthalmol, 2012, 96(4):499-502. DOI:10.1136/bjophthalmol-2011-300498.
30.	Eagle RJ, Shields CL, Bianciotto C, et al. Histopathologic observations after intra-arterial chemotherapy for retinoblastoma[J]. Arch Ophthalmol, 2011, 129(11):1416-1421. DOI:10.1001/archophthalmol.2011.223.
31.	Dunkel IJ, Shi W, Salvaggio K, et al. Risk factors for severe neutropenia following intra-arterial chemotherapy for intra-ocular retinoblastoma[J/OL]. PLoS One, 2014, 9(10):108692[2014-10-19]. http://dx.plos.org/10.1371/journal.pone.0108692. DOI:10.1371/journal.pone.0108692.
32.	Aziz HA, Lasenna CE, Vigoda M, et al. Retinoblastoma treatment burden and economic cost:impact of age at diagnosis and selection of primary therapy[J]. Clin Ophthalmol, 2012, 6:1601-1606. DOI:10.2147/OPTH.S33094.
33.	Bianciotto C, Shields CL, Iturralde JC, et al. Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma[J]. Ophthalmology, 2012, 119(4):843-849. DOI:10.1016/j.ophtha.2011.09.040.
34.	Marr BP, Hung C, Gobin YP, et al. Success of intra-arterial chemotherapy (chemosurgery) for retinoblastoma:effect of orbitovascular anatomy[J]. Arch Ophthalmol, 2012, 130(2):180-185. DOI:10.1001/archophthalmol.2011.386.
35.	Vijayakrishnan R, Shields CL, Ramasubramanian A, et al. Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma:should we be concerned?[J]. Arch Ophthalmol, 2010, 128(11):1427-1431. DOI:10.1001/archophthalmol.2010.258.
36.	Gobin YP, Rosenstein LM, Marr BP, et al. Radiation exposure during intra-arterial chemotherapy for retinoblastoma[J]. Arch Ophthalmol, 2012, 130(3):403-405. DOI:10.1001/archopthalmol.2011.2717.

1. Tamboli D, Topham A, Singh N, et al. Retinoblastoma:a SEER dataset evaluation for treatment patterns, survival, and second malignant neoplasms[J]. Am J Ophthalmol, 2015, 160(5):953-958. DOI:10.1016/j.ajo.2015.07.037.
2. Wong FL, Boice JJ, Abramson DH, et al. Cancer incidence after retinoblastoma:radiation dose and sarcoma risk[J]. JAMA, 1997, 278(15):1262-1267.
3. Chan HS, Gallie BL, Munier FL, et al. Chemotherapy for retinoblastoma[J]. Ophthalmol Clin North Am, 2005, 18(1):55-63. DOI:10.1016/j.ohc.2004.11.002.
4. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma:is chemotherapy a factor?[J]. Ophthalmology, 2007, 114(7):1378-1383. DOI:10.1016/j.ophtha.2007.03.074.
5. Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma:four-year experience[J]. Arch Ophthalmol, 2011, 129(6):732-737. DOI:10.1001/archophthalmol.2011.5.
6. Francis JH, Abramson DH. Recent advances in retinoblastoma treatment[M]. Bolin:Springer International Publishing, 2015:27-36.
7. Abramson DH, Shields CL, Munier FL, et al. Treatment of retinoblastoma in 2015:agreement and disagreement[J]. JAMA Ophthalmol, 2015, 133(11):1341-1347. DOI:10.1001/jamaophthalmol.2015.3108.
8. Yousef YA, Soliman SE, Astudillo PP, et al. Intra-arterial chemotherapy for retinoblastoma:a systematic review[J/OL]. JAMA Ophthalmol, 2016, 2016:E1[2016-03-17]. http://archopht.jamanetwork.com/article.aspx?doi=10.1001/jamaophthalmol.2016.0244. DOI:10.1001/jamaophthalmol.2016.0244.[published online ahead of print].
9. Gaudana R, Jwala J, Boddu SH, et al. Recent perspectives in ocular drug delivery[J]. Pharm Res, 2009, 26(5):1197-1216. DOI:10.1007/s11095-008-9694-0.
10. Shields CL, Shields JA. Intra-arterial chemotherapy for retinoblastoma:the beginning of a long journey[J]. Clin Experiment Ophthalmol, 2010, 38(6):638-643. DOI:10.1111/j.1442-9071.2010.02297.x.
11. Schaiquevich P, Buitrago E, Taich P, et al. Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients[J]. Invest Ophthalmol Vis Sci, 2012, 53(7):4205-4212. DOI:10.1167/iovs.12-9501.
12. Taich P, Ceciliano A, Buitrago EEA. Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma[J]. Ophthalmology, 2014, 121(4):889-897. DOI:10.1517/17425255.2014.951330.
13. Inomata M, Kaneko A. Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay[J]. Jpn J Cancer Res, 1987, 78(8):858-868.
14. Rashid OM, Sloot S, Zager JS. Regional therapy in metastatic melanoma:an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion[J]. Expert Opin Drug Metab Toxicol, 2014, 10(10):1355-1364. DOI:10.1517/17425255.2014.951330.
15. Francis JH, Abramson DH, Gaillard MC, et al. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan[J]. Ophthalmology, 2015, 122(6):1173-1179. DOI:10.1016/j.ophtha.2015.01.017.
16. Reese AB, Hyman GA, Merriam GJ, et al. Treatment of retinoblastoma by radiation and triethylenemelamine[J]. AMA Arch Ophthalmol, 1954, 53(4):505-513.
17. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma[J]. Int J Clin Oncol, 2004, 9(2):69-73.
18. Abramson DH, Dunkel IJ, Brodie SE, et al. A phaseⅠ/Ⅱstudy of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results[J]. Ophthalmology, 2008, 115(8):1398-1404. DOI:10.1016/j.ophtha.2007.12.014.
19. Zanaty M, Barros G, Chalouhi N, et al. Update on intra-arterial chemotherapy for retinoblastoma[J/OL]. Sci World J, 2014, 2014:869604[2014-10-22]. http://www.hindawi.com/journals/tswj/2014/869604/. DOI:10.1155/2014/869604.
20. 李冬梅, 高艳红, 甘慢慢, 等.超选眼动脉介入灌注美法仑治疗视网膜母细胞瘤患儿的护理[J].中华护理杂志, 2014, 49(11):1356-1358. DOI:10.3761/j.issn.0254-1769.2014.11.016.Li DM, GaoYH, Gan MM, et al. Perioperative nursing of retinoblastoma patients treated by superselective ophthalmic artery infusion of melphalan[J]. Chin J Nurs, 2014, 49(11):1356-1358. DOI:10.3761/j.issn.0254-1769.2014.11.016.
21. 张靖, 姜华, 申刚, 等.经导管眼动脉灌注化疗治疗晚期视网膜母细胞瘤30例[J].介入放射学杂志, 2014, 23(1):31-34. DOI:10.3969/j.issn.1008-794X.2014.01.009.Zhang J, Jiang H, Shen G, et al. Selective ophthalmic arterial injection therapy for advanced retinoblastoma:initial experience in 30 cases[J]. J Intervent Radiol, 2014, 23(1):31-34. DOI:10.3969/j.issn.1008-794X.2014.01.009.
22. Lumbroso-Le RL, Aerts I, Levy-Gabriel C, et al. Conservative treatments of intraocular retinoblastoma[J]. Ophthalmology, 2008, 115(8):1405-1411. DOI:10.1016/j.ophtha.2007.11.009.
23. Shields CL, Mashayekhi A, Au AK, et al. The international classification of retinoblastoma predicts chemoreduction success[J]. Ophthalmology, 2006, 113(12):2276-2280. DOI:10.1016/j.ophtha.2006.06.018.
24. Shields CL, Ramasubramanian A, Thangappan A, et al. Chemoreduction for group E retinoblastoma:comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes[J]. Ophthalmology, 2009, 116(3):544-551. DOI:10.1016/j.ophtha.2008.10.014.
25. Shields CL, Manjandavida FP, Lally SE, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes:outcomes based on the international classification of retinoblastoma[J]. Ophthalmology, 2014, 121(7):1453-1460. DOI:10.1016/j.ophtha.2014.01.026.
26. Francis JH, Abramson DH, Gobin YP, et al. Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma[J]. Ophthalmology, 2015, 122(5):1016-1022. DOI:10.1016/j.ophtha.2014.11.029.
27. 季迅达, 李家恺, 赵军阳, 等.眼内晚期视网膜母细胞瘤静脉化学治疗失败后行眼动脉介入化学治疗的疗效观察[J].中华眼底病杂志, 2015, 31(6):556-559. DOI:10.3760/cma.j.issn.1005-1015.2015.06.011.Ji XD, Li JK, Zhao JY, et al.Efficacy of intra-arterial chemotherapy for advanced retinoblastoma after failure of intravenous chemotherapy[J]. Chin J Ocul Fundus Dis, 2015, 31(6):556-559. DOI:10.3760/cma.j.issn.1005-1015.2015.06.011.
28. 刘秋玲, 王亚峰, 毛更生, 等.眼动脉介入化疗治疗眼内期视网膜母细胞瘤42例临床安全性分析[J].中华儿科杂志, 2012, 50(10):793-797. DOI:10.3760/cma.j.issn.0578-1310.2012.10.019.Liu QL, Wang YF, Mao GS, et al.Analysis on the safety of ophthalmic artery cannulation for intra-arterial chemotherapy in 42 patients with intraocular stage retinoblastoma[J]. Chin J Pediatr, 2012, 50(10):793-797.DOI:10.3760/cma.j.issn.0578-1310.2012.10.019.
29. Abramson DH, Marr BP, Dunkel IJ, et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding:2-year results[J]. Br J Ophthalmol, 2012, 96(4):499-502. DOI:10.1136/bjophthalmol-2011-300498.
30. Eagle RJ, Shields CL, Bianciotto C, et al. Histopathologic observations after intra-arterial chemotherapy for retinoblastoma[J]. Arch Ophthalmol, 2011, 129(11):1416-1421. DOI:10.1001/archophthalmol.2011.223.
31. Dunkel IJ, Shi W, Salvaggio K, et al. Risk factors for severe neutropenia following intra-arterial chemotherapy for intra-ocular retinoblastoma[J/OL]. PLoS One, 2014, 9(10):108692[2014-10-19]. http://dx.plos.org/10.1371/journal.pone.0108692. DOI:10.1371/journal.pone.0108692.
32. Aziz HA, Lasenna CE, Vigoda M, et al. Retinoblastoma treatment burden and economic cost:impact of age at diagnosis and selection of primary therapy[J]. Clin Ophthalmol, 2012, 6:1601-1606. DOI:10.2147/OPTH.S33094.
33. Bianciotto C, Shields CL, Iturralde JC, et al. Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma[J]. Ophthalmology, 2012, 119(4):843-849. DOI:10.1016/j.ophtha.2011.09.040.
34. Marr BP, Hung C, Gobin YP, et al. Success of intra-arterial chemotherapy (chemosurgery) for retinoblastoma:effect of orbitovascular anatomy[J]. Arch Ophthalmol, 2012, 130(2):180-185. DOI:10.1001/archophthalmol.2011.386.
35. Vijayakrishnan R, Shields CL, Ramasubramanian A, et al. Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma:should we be concerned?[J]. Arch Ophthalmol, 2010, 128(11):1427-1431. DOI:10.1001/archophthalmol.2010.258.
36. Gobin YP, Rosenstein LM, Marr BP, et al. Radiation exposure during intra-arterial chemotherapy for retinoblastoma[J]. Arch Ophthalmol, 2012, 130(3):403-405. DOI:10.1001/archopthalmol.2011.2717.

Previous Article
Research updates on the correlation of hypertensive retinopathy and carotid artery lesion
Next Article
The evaluation and treatment of cyclodialysis clefts

Chinese Journal of Ocular Fundus Diseases

The progress of intra-arterial chemotherapy for retinoblastoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content